- Home
- Companies
- usa california
- cancer genomics treatment
Show results for
Refine by
Cancer Genomics Treatment Suppliers In Usa California
38 companies found
based inSan Diego, CALIFORNIA (USA)
We are dedicated to one thing: improving outcomes for cancer patients. That’s why we focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy. ...
based inPalo Alto, CALIFORNIA (USA)
Varian Medical Systems, Inc., headquartered globally in Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and ...
Fast, precise planning for advanced cancer care. The Eclipse treatment planning system has been developed and advanced with the collaboration of clinicians to be better able to treat their patients. Thousands of hospitals and cancer treatment ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of ...
based inSan Diego, CALIFORNIA (USA)
CureMetrix is committed to the advancement of technology that will improve cancer survival rates worldwide. Our research is focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis ...
based inMountain View, CALIFORNIA (USA)
iPSCs- a revolutionary discovery with untapped potential. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells ...
iPSC vaccination presents a differentiated approach to cancer treatment, targeting a panoply of antigens, leveraging the patient's immune system for optimized antigen presentation, and engaging both cellular and humoral ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inBerkeley, CALIFORNIA (USA)
InterX, led by Nobel Prize-winning scientists, is developing tools for pharmaceutical ligand design, material science, and biochemistry. We leverage our proprietary software tools for internal molecule development work, as well as joint ventures. ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
based inSan Francisco, CALIFORNIA (USA)
Motic Digital Pathology addresses the growing global pathology care gap by making digital medicine approachable for hospitals, labs, and doctors everywhere. We promote adoption of telepathology through our innovative, cost-effective solutions ...
based inSherman Oaks, CALIFORNIA (USA)
T-Cure is a clinical-stage immuno-oncology company developing the next generation of T cell therapies for patients with solid tumors. It is committed to bringing new targets and therapies to the T-Cell Receptor (TCR) field that have a high ...
based in, CALIFORNIA (USA)
AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity ...
AIVITA Biomedical is using its patient-specific vaccine platform to develop a rapidly scalable vaccine candidate, AV-COVID-19, for the novel coronavirus (SARS-CoV-2). AIVITA’s personalized vaccine begins with a basic blood draw, from which the ...
based inSanta Barbara, CALIFORNIA (USA)
Owl Biomedical, Inc. was founded in 2011 to expand the use of its exclusive cell sorting MEMS technology for cell therapy, cancer diagnostics and basic research. Operating in Santa Barbara, California, Owl Biomedical was purchased in 2013 by ...
based inSan Diego, CALIFORNIA (USA)
CureMatch, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for ...
CureMatch provides a scored and ranked listing of the most well-adapted personalized medicine treatment options. The comprehensive analysis considers commonly used treatments, as well as targeted therapy, immunotherapy, hormone therapy, and newly ...
based inIrvine, CALIFORNIA (USA)
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on ...
MDxHealth’s technology platform is called methylation-specific PCR (MSP), which is a proprietary DNA-based technology that functions on standard commercial PCR equipment. MSP is extremely powerful and accurate with the ability to detect a ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
based inLa Jolla, CALIFORNIA (USA)
Avelas is a clinical-stage drug-device company pioneering the field of fluorescence imaging for real-time cancer detection. Avelas is focused on the development and commercialization of pegloprastide (also referred to as “AVB-620”), a novel ...
Pegloprastide (AVB-620) is based on the science of activatable cell-penetrating peptides and is designed to deliver a fluorescent marker specifically to cancer cells to enable surgeons to identify cancerous tissue in real-time and thus, avoid repeat ...
based inSan Francisco, CALIFORNIA (USA)
Videra Surgical is an oncology surgery company, focusing on breast cancer treatment. Videra is committed to improving the lives of breast cancer patients who undergo radiation therapy following lumpectomy. With breast cancer surgery, helping the ...
based inSan Diego, CALIFORNIA (USA)
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on ...
With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. This is a major advance over ...
based inSan Jose, CALIFORNIA (USA)
Our transformative vision for the future of radiation therapy began with the breakthrough development of our miniaturized x-ray source – so small, it could fit on the tip of your finger. Today, this proprietary technology, combined with the ...
The versatile Xoft Axxent Electronic Brachytherapy (eBx) System utilizes state-of-the-art 50kV x-ray technology to provide expanded treatment options for a range of cancers. The Xoft System provides isotope-free HDR therapeutic radiation of the ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the ...